首页
期刊简介
编 委 会
期刊订阅
百年学会 医星璀璨
名院风范
学科风华
菁英风采
投稿须知
过刊浏览
联系我们
篇名
关键词
作者
作者单位
摘要
关键词
注册本刊作者
作者投稿查稿
专家远程审稿
编辑在线审稿
编务办公专区
主编办公专区
下载文档
《上海医学》审稿费代缴委托书
《上海医学》杂志2024年征订启事
《上海医学》期刊编审系统审稿专家使用手册
工作动态
03-05
《上海医学》杂志2024年度“春蕾杯”论文评比征文通知
06-14
创新驱动,培育人才—《上海医学》2021年度春蕾计划评审结果揭晓
01-21
《上海医学》期刊影响力指标和学科排名取得显著提升
01-20
《上海医学》恭祝大家新年快乐!
08-18
作废声明
联系方式
发行周期:
月刊
主管单位:
上海市卫生健康委员会
主办单位:
上海市医学会
编辑出版:
《上海医学》编辑部
联系地址:
上海市北京西路1623号
邮编:
200040
电话:
021-62178606
传真:
021-62178606
邮箱:
smasmj@shsma.org.cn
ISSN:
ISSN0253-9934
CN:
CN31-1366/R
收款账号:
1001255309008900719
账户名:
上海市医学会
开户行:
工商银行上海市静安寺支行
友情链接
上海市医学会
当前位置:首页 >
子宫肌腺症保守治疗的分级方案选择初探
Classified conservative treatment of adenomyosis—a preliminary observation
浏览(676) 下载(0)
DOI:
作者:
方芳
Fang Fang
作者单位:
复旦大学附属妇产科医院
Obstetrics and Gynecology Hospital of Fudan University
关键词:
子宫肌腺症 保守治疗 GnRHa 左炔诺孕酮宫内节育系统
adenomyosis, conservative treatment, gonadotropin-releasing hormone agonist, levonorgestrel-releasing intrauterine system
摘要:
[摘要] 目的 观察促性腺激素释放激素激动剂(GnRHa)和左炔诺孕酮宫内节育系统(LNG-IUS)分级治疗方案对于子宫不同程度增大的子宫肌腺症的疗效。方法 采用GnRHa和LNG-IUS联合应用的不同方案治疗子宫增大程度不同的子宫肌腺症并随访36个月,观察对缩小子宫体积、缓解痛经、降低血CA125水平的作用及治疗转归。结果 对子宫体平均径线不超过65mm者,单用曼月乐及联合GnRHa治疗均可缓解痛经(p<0.05)并持续36个月以上,可减小子宫体积达24个月。对子宫平均径线在65mm~85mm者,GnRHa3针后联合曼月乐治疗第一个月即可缩小子宫且持续12个月;抑制痛经作用持续时间达36个月。对子宫平均径线超过85mm者,GnRHa6针后联合曼月乐治疗可快速缩小子宫并持续至放环后6个月;抑制痛经效果可持续至放环后12个月。GnRHa治疗3针可使血CA125水平从113.5±97.1U/ml降为23.2±5.1U/ml(p<0.05);单用曼月乐可在6个月内使CA125水平从63.5±21.6U/ml降为30.8±12.3U/ml(p<0.05)。结论 GnRHa可快速缩小子宫、抑制痛经及降低CA125水平;曼月乐也具有上述作用,但作用效果较GnRHa慢而弱。GnRHa-曼月乐联合治疗对于子宫轻到中度增大者疗效可维持至少2~3年,但对子宫重度增大者持续时间不到2年。
[Abstract] Objectives: To evaluate the clinical outcomes of classified conservation treatment of adenomyosis using combined levonorgestrel-releasing intrauterine system (LNG-IUS) with gonadotropin-releasing hormone agonist (GnRHa),. Methods: Using combined LNG-IUS with GnRHa, classified treatments were applied for 92 patients suffered from adenomyosis with 3 degrees enlarged uterus. Effects on reducing the uterine volume, alleviating dysmenorrheal and lowering blood level of CA125 were observed for 36 months follow-up. Results: Treating the patients with average diameters of uterus less than 65mm, LNG-IUS solely or combined with GnRHa both can alleviate and lasts more than 36 months, and reduce the volume of uterus for 24 months. For the patients with average diameters of uterus within the range of 65mm~85mm, treating with GnRHa for 3 cycles stepped by LNG-IUS can reduce the uterine volume with 1 month and last for 12 months, while dysmenorrhea can be alleviated for 36 months. For those patients with with average diameters of uterus more than 85mm, 6 cycles of GnRHa stepped by LNG-IUS can also rapidly alleviate dysmenorrhea and reduce uterine volume, but such effect can only last 6~12 months. Average CA125 level declines from 113.5±97.1U/ml to 23.2±5.1U/ml(p<0.05)after 3 cycles treatment of GnRHa sole or combined with LNG-IUS. Meanwhile, treating with LNG-IUS sole, average CA125 level declines from 63.5±21.6U/ml to 30.8±12.3U/ml(p<0.05)within 6 months. Conclusions: GnRHa can rapidly alleviate dysmenorrhea, reduce uterine volume and CA125 level in patients with adenomyosis. LNG-IUS also has such effect but works more slowly and weakly than GnRHa. Combined treatment efficacy of LNG-IUS with GnRHa could maintain at least 2~3 years for the adenomyosis patients with mild or medium enlarged uterus. Thus, such efficacy can only last less than 2 years for those have severely enlarged uterus.
点击下载DOC全文